Towards the use of Epigenetic Therapy as a Primer for Cancer Immunotherapy
Towards the use of Epigenetic Therapy as a Primer for Cancer Immunotherapy
批准号:
340667
负责人:
De Carvalho Daniel
金额:
$21.86万
依托单位国家:
加拿大
项目类别:
Salary Programs
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-12-01 至 2020-12-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The main premise of Cancer Immunotherapy is to stimulate the patient's immune system to attack the malignant tumour cells. Recent progress in cancer immunotherapy protocols has led to exciting clinical results in several types of solid tumours. However, f
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair - Tier 2
-
批准号:453871
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2020
-
负责人:De Carvalho Daniel
-
依托单位:
Viral mimicry tolerance as a mechanism of early tumor immune evasion
-
批准号:402508
-
项目类别:Operating Grants
-
资助金额:$63.25万
-
财政年份:2019
-
负责人:De Carvalho Daniel
-
依托单位:
CRC Tier 2
-
批准号:364801
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2016
-
负责人:De Carvalho Daniel
-
依托单位:
DNA Methylation Inhibitors for Colorectal Cancer Therapy - Implications for Cancer Immunotherapy
-
批准号:342880
-
项目类别:Operating Grants
-
资助金额:$69.34万
-
财政年份:2016
-
负责人:De Carvalho Daniel
-
依托单位:
Epigenetic Approaches to Enhance Cancer Immunotherapy and to Target Cancer Initiating Cells
-
批准号:333656
-
项目类别:Operating Grants
-
资助金额:$93.83万
-
财政年份:2015
-
负责人:De Carvalho Daniel
-
依托单位:
海外基金